MTHFD1
Basic information
Region (hg38): 14:64388031-64463457
Previous symbols: [ "MTHFC", "MTHFD" ]
Links
Phenotypes
GenCC
Source:
- combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia | AR | Allergy/Immunology/Infectious; Audiologic/Otolaryngologic; Biochemical | Individuals have been described as presenting with severe and recurrent infections, as well as other sequelae, such as renal disease, and medical management (with folate and hydroxycobalamin) has been described as beneficial; In addition to folate and hydroxycobalamin treatment, antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; Related to hearing deificits, early recognition and treatment of hearing impairment may improve outcomes, including speech and language development | Allergy/Immunology/Infectious; Audiologic/Otolaryngologic; Biochemical; Hematologic; Neurologic; Renal | 23296427; 25633902; 27707659 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (9 variants)
- Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MTHFD1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 118 | 123 | ||||
missense | 177 | 190 | ||||
nonsense | 10 | |||||
start loss | 0 | |||||
frameshift | 5 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 7 | |||||
splice region | 14 | 23 | 2 | 39 | ||
non coding | 78 | 14 | 97 | |||
Total | 9 | 15 | 184 | 202 | 22 |
Highest pathogenic variant AF is 0.0000131
Variants in MTHFD1
This is a list of pathogenic ClinVar variants found in the MTHFD1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
14-64388445-C-T | Benign (Dec 09, 2023) | |||
14-64388451-C-A | Uncertain significance (Nov 03, 2021) | |||
14-64388456-A-G | Uncertain significance (Feb 25, 2022) | |||
14-64388457-G-A | Likely benign (Mar 20, 2023) | |||
14-64388481-CATT-C | Likely benign (Aug 08, 2023) | |||
14-64388482-ATTG-A | Likely benign (Nov 23, 2022) | |||
14-64400804-C-T | MTHFD1-related disorder | Likely benign (Jan 31, 2024) | ||
14-64400805-G-A | Likely benign (Oct 15, 2023) | |||
14-64400819-A-G | Uncertain significance (Jul 11, 2021) | |||
14-64400855-C-T | Uncertain significance (May 13, 2021) | |||
14-64400860-C-T | Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia;Neural tube defects, folate-sensitive | Uncertain significance (Mar 30, 2021) | ||
14-64400861-G-A | Inborn genetic diseases | Uncertain significance (Nov 03, 2023) | ||
14-64400871-A-G | Uncertain significance (Oct 19, 2022) | |||
14-64400874-A-G | Likely benign (Feb 25, 2023) | |||
14-64400885-G-A | Likely benign (Sep 21, 2022) | |||
14-64400890-T-C | Likely benign (Jul 09, 2023) | |||
14-64411072-A-G | Likely benign (Jul 19, 2023) | |||
14-64411078-T-C | Likely benign (Apr 09, 2023) | |||
14-64411081-T-C | Likely benign (May 11, 2022) | |||
14-64411098-C-T | Likely benign (Oct 13, 2023) | |||
14-64411109-C-T | Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia • Severe combined immunodeficiency disease | Pathogenic/Likely pathogenic (Jan 01, 2024) | ||
14-64411114-CTT-C | Pathogenic (Nov 14, 2023) | |||
14-64411115-T-C | Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia | Likely pathogenic (Oct 15, 2018) | ||
14-64411124-A-G | Inborn genetic diseases | Uncertain significance (Aug 12, 2021) | ||
14-64411151-T-TA | Likely benign (Mar 14, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MTHFD1 | protein_coding | protein_coding | ENST00000216605 | 27 | 71974 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00446 | 0.996 | 125695 | 0 | 53 | 125748 | 0.000211 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.68 | 405 | 512 | 0.791 | 0.0000293 | 6110 |
Missense in Polyphen | 128 | 205.23 | 0.62368 | 2472 | ||
Synonymous | -0.172 | 197 | 194 | 1.02 | 0.0000123 | 1871 |
Loss of Function | 4.62 | 14 | 48.8 | 0.287 | 0.00000249 | 601 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000365 | 0.000366 |
Ashkenazi Jewish | 0.000596 | 0.000595 |
East Asian | 0.000272 | 0.000272 |
Finnish | 0.000370 | 0.000370 |
European (Non-Finnish) | 0.000211 | 0.000211 |
Middle Eastern | 0.000272 | 0.000272 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Disease
- DISEASE: Neural tube defects, folate-sensitive (NTDFS) [MIM:601634]: The most common NTDs are open spina bifida (myelomeningocele) and anencephaly. {ECO:0000269|PubMed:12384833, ECO:0000269|PubMed:16552426, ECO:0000269|PubMed:9611072}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:17000706}. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry.; DISEASE: Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia (CIMAH) [MIM:617780]: An autosomal recessive disorder due to an inborn error of folate metabolism. Variable clinical manifestations include hemolytic uremic syndrome, macrocytosis, epilepsy, hearing loss, retinopathy, mild mental retardation, and lymphopenia. {ECO:0000269|PubMed:21813566, ECO:0000269|PubMed:25633902, ECO:0000269|PubMed:27707659}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Antimetabolite Pathway - Folate Cycle, Pharmacodynamics;One carbon pool by folate - Homo sapiens (human);Methotrexate Pathway (Cancer Cell), Pharmacodynamics;Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics;Folate malabsorption, hereditary;Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);Methotrexate Action Pathway;Folate Metabolism;Folate Metabolism;One Carbon Metabolism;Trans-sulfuration and one carbon metabolism;folate polyglutamylation;Folate metabolism;Metabolism;folate transformations I;Metabolism of folate and pterines;histidine degradation;Metabolism of water-soluble vitamins and cofactors;Metabolism of vitamins and cofactors;Vitamin B9 (folate) metabolism;tetrahydrofolate salvage from 5,10-methenyltetrahydrofolate
(Consensus)
Recessive Scores
- pRec
- 0.210
Intolerance Scores
- loftool
- 0.790
- rvis_EVS
- 0.38
- rvis_percentile_EVS
- 75.63
Haploinsufficiency Scores
- pHI
- 0.780
- hipred
- Y
- hipred_score
- 0.793
- ghis
- 0.517
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.553
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | High |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Mthfd1
- Phenotype
- immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype;
Gene ontology
- Biological process
- histidine biosynthetic process;neutrophil homeostasis;neural tube closure;purine nucleotide biosynthetic process;methionine metabolic process;one-carbon metabolic process;heart development;serine family amino acid metabolic process;serine family amino acid biosynthetic process;methionine biosynthetic process;purine nucleobase biosynthetic process;10-formyltetrahydrofolate biosynthetic process;transsulfuration;tetrahydrofolate interconversion;folic acid metabolic process;embryonic neurocranium morphogenesis;embryonic viscerocranium morphogenesis;oxidation-reduction process;somite development
- Cellular component
- cytoplasm;mitochondrion;cytosol;membrane;extracellular exosome
- Molecular function
- formate-tetrahydrofolate ligase activity;methenyltetrahydrofolate cyclohydrolase activity;methylenetetrahydrofolate dehydrogenase [NAD(P)+] activity;methylenetetrahydrofolate dehydrogenase (NAD+) activity;methylenetetrahydrofolate dehydrogenase (NADP+) activity;protein binding;ATP binding